Immunotherapy for advanced gastric cancer

Figure 1 The molecular findings in gastric cancer by The Cancer Genome Atlas compared with the Asian Cancer Research Group. TCGA: The Cancer Genome Atlas; ACRG: Asian Cancer Research Group; EGFR: Epithelial growth factor receptor; CIN: Chromosomal instability; HER: Human epidermal growth factor receptor; FGFR2: Fibroblast growth factor receptor 2; MSI: Microsatellite instability; GS: Genomically stable; EBV: Epstein-Barr virus; PD-L1/2: Programmed death ligand-1/2; RTKs: Receptor tyrosine kinases; RAS: Rat sarcoma virus; ERBB2/3: Erb-b2 receptor tyrosine kinase 2/3; JAK2: Janus-associated kinase 2; MLH1: MutL protein homolog 1; MSH: Melanocyte-stimulating hormones; CDKN2A: Cyclin-dependent kinase inhibitor 2A; PI3K: Phosphatidylinositol-3-kinase; ARID1A: AT-rich interactive domain-containing protein 1A; BCOR: B-cell lymphoma 6 corepressor; MSS: Microsatellite stable; TP53: tumor protein 53; MYC: Myelocytomatosis oncogene; GATA6: GATA binding protein 6; MMR: Measles-mumps-rubella; CDH1: Cadherin 1; EMT: Epithelial-mesenchymal transition; E-CAD: E-cadherin; ALK: Anaplastic lymphoma kinase.